CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Deciding between broad market and sector funds depends on diversification needs and risk tolerance. This guide compares outcomes and helps you decide.
28,547 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Mercadolibre hits $14.5 billion in annual sales, marking a major milestone for Latin America's e-commerce and fintech...
Alphabet stands out as a durable cash engine blending a near-monopoly ad business with AI-driven cloud gains, offerin...
Oil surged past the $100 mark again on March 12, 2026, after the U.S. signaled limits to protecting the Strait of Hor...
When a veteran value investor piles into a beaten-down name, traders take notice. Prem Watsa recently added to his Un...
A push to name Kevin Warsh Fed Chair roils markets, sending XRP into a fresh swing as traders weigh policy, liquidity...
India restricts Telegram access ahead of the NEET-UG re-exam, hitting hundreds of millions of users and sending Gram ...
Traders are turning toward three mid-cap miners as the tape says these growth stocks could ride higher metal prices a...
SpaceX's hypothetical IPO sent SPCX to the mid-180s, valuing the company near $2.44 trillion. Analysts warn the rally...
PayPal faces a tough stretch in the public eye, yet cash flow and a disciplined capital plan hint at upside. Here’s w...
ServiceNow stock sits in the mid-$90s as AI disruption reshapes enterprise software. This article lays out a fresh 20...
Zoom's post-pandemic growth trajectory remains uncertain as investors weigh AI opportunities and competition. This pi...